The 100% Pharma Tariff Has a Back Door — 26 Companies Already Walked Through

The default rate from the April 2, 2026 White House proclamation is 100% ad valorem on any imported drug or API under an active U.S. patent — high enough to make the marginal import unviable for any price-sensitive buyer. The law carves three off-ramps. A country exemption reduces the rate to 15% for products of Japan, EU member states, South Korea, Switzerland and Liechtenstein, and to 10% for the United Kingdom (reducible to zero under a future bilateral deal). A specialty carve-out — codified in the Sept. 23 Federal Register guidance — zeroes the duty on orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates, and medical countermeasures. And an opt-in pathway lets any manufacturer drop the rate to 20% with a U.S. onshoring plan, or to zero through Jan. 20, 2029 if that plan is paired with a Most-Favored-Nation (MFN) pricing deal with HHS.

The single largest tariff-avoidance bloc is the MFN list, which the White House expanded to 26 companies on Aug. 31, 2026 — covering, by the administration's count, 89% of the U.S. branded-drug market. The second wave added Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB, alongside the original signatories announced earlier in the year. The same announcement committed the nine new entrants to invest at least $19.6 billion collectively in U.S. manufacturing, plus donations to the Strategic Active Pharmaceutical Ingredients Reserve: Teva shipped 45 metric tons of metronidazole and 4.8 tons of amlodipine; Astellas sent 25 kg of tacrolimus. The Council of Economic Advisers puts the ten-year patient-savings number at roughly $600 billion.

Bayer's Oct. 2, 2026 New Albany announcement is the largest single onshoring pledge since the proclamation: $2.2 billion, 600 jobs, drug-substance and drug-product modules, first output in 2031. It targets oncology, cardiovascular and renal-care drugs — Bayer's post-Xarelto growth portfolio — and stacks on top of more than $7 billion the company has already spent on U.S. pharma R&D and manufacturing in the past five years. The 20% rate under the onshoring pathway rather than 100% makes the math work, but only across a five-year horizon, not the four years the build-out will take. Two days of headlines did not move the tariff math; the plant does.

Bristol-Myers Squibb's Aug. 10, 2026 Houston announcement is the template Bayer is now copying: a $2.3 billion, 600,000-square-foot multi-modal campus at Generation Park, ~500 jobs, covering small molecules, biologics and ADCs. It is part of Bristol-Myers Squibb's $40 billion U.S. investment commitment over five years, and it puts manufacturing for Eliquis-adjacent oncology and cardiovascular drugs onshore just as the tariff bites. The bigger peer pledges stack up: Novartis is committing $23 billion to expand ten U.S. facilities over five years (per Reuters, Aug. 10, 2026), and Eli Lilly is on the same onshoring track. Industry-wide, Think Global Health tallied more than $480 billion in cumulative U.S. onshoring pledges by late 2025.

The drug doesn't go from API supplier to patient without passing through the Big 3 U.S. distributors — and that pipeline is where the 100% tariff becomes a balance-sheet problem before it becomes a price problem. McKesson, Cencora and Cardinal Health together moved nearly $1 trillion of pharmaceuticals in the trailing twelve months — McKesson at $411B, Cencora at $332.8B, Cardinal Health at $254.2B — against days-of-inventory outstanding of 24, 24 and 26 days respectively. They are running 23- to 27-day inventory turn at gross margins of just 3.6% to 3.8%. A 100% duty applied to a single imported patented SKU lands almost entirely in distributors' working capital until contracts reset, because they cannot immediately renegotiate formulary pricing with payers.

The downstream channel CVS Health — which owns Caremark, the largest U.S. PBM — runs a $412.6B revenue book split across pharmacy retail, the Caremark PBM, and Aetna health benefits. Its 1.3% net margin makes any tariff pass-through delay directly visible in quarterly earnings, while its rebate-spread model means the CVS Health Services PBM absorbs much of the gross-to-net whiplash before it reaches the patient. The pricing signal travels from manufacturer → distributor → PBM → plan sponsor over roughly 90 to 180 days under current contracting; the 100% duty's first-round impact lands at the distributor step.

The tariff excludes generic drugs and their APIs \"at this time,\" but a one-year review built into the proclamation determines whether the 100% wall extends to that segment, too. The clock matters because generics account for roughly 90% of U.S. prescriptions and run almost entirely on China- and India-sourced APIs. A separate generic-drug tariff schedule the White House set in July 2026 keeps imports duty-free for two years from Aug. 1, 2026, then slaps a 100% tariff for one year, then 200% for any manufacturer still sourcing abroad. China-sourced generics run 20-30% cheaper than Indian production, so the duty does not close the underlying cost gap — it raises the U.S. bill.

For patented drugs the picture is the same. Bayer's Xarelto (rivaroxaban) — Bayer's flagship stroke and clot-prevention drug, with €540M in Q3 2025 sales as the patent erodes — sources its active ingredient from roughly 40 Indian producers and 22 Chinese producers, per supplier registry data; Bristol-Myers Squibb and Pfizer's Eliquis (apixaban) similarly runs on Indian and Chinese API. The Section 232 tariff hits those APIs at 100% unless the manufacturer qualifies under one of the three doors. Neither Bayer nor BMS is on the Aug. 31 MFN list, so both are choosing between the 20% onshoring rate and the 100% default until the Ohio and Houston plants ramp.

The 100% tariff has, in effect, split global pharma into a protected tier and an exposed tier — and the protected tier is much bigger than the headline suggests. The MFN bloc covers 89% of U.S. branded volume, country exemptions cover most EU and Japanese imports at 15%, and specialty carve-outs cover a meaningful share of high-value oncology and rare-disease launches. The unprotected tier is the residual: smaller manufacturers without MFN deals, non-specialty patented drugs sourced from non-exempt countries, and the patented-API tail where Indian and Chinese producers still hold the cost advantage. That's where the 100% rate binds.

Short-term, that pushes three stock-level effects. First, MFN signatories capture a relative pricing advantage as competitors either sign (and accept MFN pricing) or face the 100% wall — Teva and Astellas are the clearest beneficiaries because their U.S. import dependence is highest and their MFN deals are freshest. Second, distributors and PBMs face a working-capital and gross-to-net squeeze until 2027 contracting cycles reset — McKesson, Cencora, Cardinal Health and CVS Health carry that transition cost on their Q4 2026 and FY 2027 books. Third, the onshoring pipeline translates into long-duration revenue capture for Bayer, Bristol-Myers Squibb, Novartis and Eli Lilly, but only from 2030 onward, well after the tariff pain hits.

Long-term, the 100% wall is a forcing function for U.S. capacity, not a permanent revenue line. By 2029 the MFN exemption sunsets; by 2030 the onshoring 20% discount expires; and by 2028 the generic-drug clock forces a separate set of decisions. The companies that survive the three-to-five-year transition intact will be those whose U.S. capacity is already operational — which is why Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Pfizer (with its January 2026 access deal) screen as defensive, while the distributors and the uncommitted specialty players carry the most transition risk.